Difference between revisions of "Dabrafenib (Tafinlar)"
Jump to navigation
Jump to search
m (→Also known as) |
|||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: BRAF kinase inhibitor. Dabrafenib inhibits some mutated BRAF kinases, such as BRAF V600E, BRAF V600K, and BRAF V600D. Some BRAF mutations such as BRAF V600E cause constitutive activation of the BRAF pathway, which drives tumor cell growth.<ref name="insert">[http://us.gsk.com/products/assets/us_tafinlar.pdf Dabrafenib (Tafinlar) package insert]</ref><ref>[[Media:Dabrafenib.pdf|Dabrafenib (Tafinlar) package insert (locally hosted backup)]]</ref> | + | Class/mechanism: BRAF kinase inhibitor. Dabrafenib inhibits some mutated BRAF kinases, such as BRAF V600E, BRAF V600K, and BRAF V600D. Some BRAF mutations such as BRAF V600E cause constitutive activation of the BRAF pathway, which drives tumor cell growth.<ref name="insert">[http://us.gsk.com/products/assets/us_tafinlar.pdf Dabrafenib (Tafinlar) package insert]</ref><ref>[[Media:Dabrafenib.pdf|Dabrafenib (Tafinlar) package insert (locally hosted backup)]]</ref><ref>[http://tafinlar.com Tafinlar manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 12: | Line 10: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://us. | + | *[http://www.pharma.us.novartis.com/product/pi/pdf/tafinlar.pdf Dabrafenib (Tafinlar) package insert]<ref name="insert"></ref> |
| − | |||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*5/29/2013: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354199.htm FDA approved] "for the treatment of patients with unresectable or metastatic [[Melanoma | melanoma with BRAF V600E mutation]] as detected by an FDA-approved test."<ref name="insert"></ref> | *5/29/2013: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm354199.htm FDA approved] "for the treatment of patients with unresectable or metastatic [[Melanoma | melanoma with BRAF V600E mutation]] as detected by an FDA-approved test."<ref name="insert"></ref> | ||
| + | *1/10/2014: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm381159.htm FDA approved] to be used together with [[Trametinib (Mekinist)]] "for the treatment of patients with unresectable or metastatic [[melanoma]] with BRAF V600E or V600K mutations as detected by an FDA-approved test." | ||
==Also known as== | ==Also known as== | ||
| − | C23H20F3N5O2S2•CH4O3S, Dabrafenib mesylate, GSK2118436, GSK-2118436A, N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene sulfonamide, methanesulfonate salt. | + | *C23H20F3N5O2S2•CH4O3S, Dabrafenib mesylate, GSK2118436, GSK-2118436A, N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene sulfonamide, methanesulfonate salt. |
==References== | ==References== | ||
Revision as of 07:04, 11 November 2015
General information
Class/mechanism: BRAF kinase inhibitor. Dabrafenib inhibits some mutated BRAF kinases, such as BRAF V600E, BRAF V600K, and BRAF V600D. Some BRAF mutations such as BRAF V600E cause constitutive activation of the BRAF pathway, which drives tumor cell growth.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 5/29/2013: FDA approved "for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test."[1]
- 1/10/2014: FDA approved to be used together with Trametinib (Mekinist) "for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test."
Also known as
- C23H20F3N5O2S2•CH4O3S, Dabrafenib mesylate, GSK2118436, GSK-2118436A, N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene sulfonamide, methanesulfonate salt.